Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Recent & Breaking News (NDAQ:DCTH)

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Business Wire November 8, 2024

Delcath Systems to Participate in Upcoming Investor Conferences

Business Wire November 1, 2024

Delcath Systems to Host Third Quarter 2024 Earnings Call

Business Wire October 25, 2024

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Business Wire October 17, 2024

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 20, 2024

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT(TM) in Metastatic Uveal Melanoma Subgroups

Business Wire September 16, 2024

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

Business Wire August 28, 2024

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire August 28, 2024

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Business Wire August 27, 2024

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

Business Wire August 26, 2024

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

Business Wire August 20, 2024

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 12, 2024

Delcath Systems Reports Second Quarter 2024 Results and Business Highlights

Business Wire August 5, 2024

Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT(TM)

Business Wire August 5, 2024

Delcath Systems to Participate in Upcoming Investor Conferences

Business Wire July 30, 2024

Delcath Systems to Host Second Quarter 2024 Earnings Call

Business Wire July 22, 2024

Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

Business Wire May 28, 2024

Delcath Systems Reports First Quarter 2024 Results and Business Highlights

PR Newswire May 14, 2024

Delcath Systems to Host First Quarter 2024 Earnings Call

PR Newswire May 7, 2024

Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT

PR Newswire May 6, 2024